Evidence map›Paper›PMID 39403120›Full record

ArticleFrontiers in allergy2024

Low CD46 expression on activated CD4

Julie Stichova, Peter Slanina, Zita Chovancova, Jan Baros, Marek Litzman, Jiri Litzman, Marcela Vlkova

Abstract read
In one paragraph

Article in Frontiers in allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julie StichovaFaculty of Medicine, Institute of Clinical Immunology and Allergology, Masaryk University, Brno, Czechia.
Peter SlaninaFaculty of Medicine, Institute of Clinical Immunology and Allergology, Masaryk University, Brno, Czechia.
Zita ChovancovaFaculty of Medicine, Institute of Clinical Immunology and Allergology, Masaryk University, Brno, Czechia.
Jan BarosFaculty of Medicine, Institute of Clinical Immunology and Allergology, Masaryk University, Brno, Czechia.
Marek LitzmanDepartment of Economics, Faculty of Business and Economics, Mendel University, Brno, Czechia.
Jiri LitzmanFaculty of Medicine, Institute of Clinical Immunology and Allergology, Masaryk University, Brno, Czechia.
Marcela VlkovaFaculty of Medicine, Institute of Clinical Immunology and Allergology, Masaryk University, Brno, Czechia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Previous research showed that the intracellular complement system, with CD46 as its central molecule, regulates the Th1 response associated with IFN-γ production and transition to a type 1 regulatory response (Tr1) characterized by IL-10 production. This transition can be influenced by a vitamin D (calcitriol), favouring a shift towards Tr1 cells and increased IL-10 production, as described in some autoimmune diseases. Objective: It is unknown whether calcitriol modulates CD46-induced Th1 response towards regulatory type 1 T cells (Tr1) in allergic eosinophilic asthma and its value in relation to reducing inflammatory response. Methods: CD4 Results: CD4 Conclusion: Our results suggest the potential existence of a key for stratifying individuals suitable for calcitriol treatment in the context of low serum vitamin D levels. After validation in clinical studies, this key could be used as an adjunctive therapy not only for patients with allergic eosinophilic asthma, but also for other diseases.

Indexed as

allergic eosinophilic asthmacalcitriolCD46IFN-γIL-10

Identifiers

PMID39403120
PMCPMC11472004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.